17
Significant Shift in UPC Pharma Patent Litigation: Sanofi’s Recent Actions
Sanofi’s recent infringement lawsuits at the Unified Patent Court (UPC) mark a pivotal moment for pharmaceutical patent litigation. Background: Sanofi’s Jevtana (cabazitaxel), used for treating metastatic castration-resistant prostate cancer (mCRPC), has faced competition from generics since its regulatory exclusivity expired in March 2021. Sanofi’s market exclusivity now hinges on its medical use patent (EP 2,493,466), […]